Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) to Execute Clinical Studies on Oral Forms of Nicotine Delivery Using DehydraTECH
LXRP’s DehydraTECH research funded by a partner that will provide $1 million, with an option for millions more LXRP subsidiary Lexaria Nicotine LLC recently entered a definitive investment agreement to receive R&D funding in exchange for equity and licensing rights In exchange, partner received minority equity interest in the subsidiary Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) will conduct a comprehensive series of clinical studies on oral forms of nicotine delivery utilizing its DehydraTECH absorption platform. Under an investment agreement by its wholly owned subsidiary, Lexaria Nicotine LLC, a partner will provide $1 million toward research on nicotine consumer products…